GlassScriptPhysician profile
Thomas J Corredine
NPI 1417214214
$5,913.24
in general payments reported to CMS, 2019-2025
27 companies · $2,328 in 2025
The $2,328 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.00 · 2020: $12.52 · 2021: $137 · 2022: $855 · 2023: $1,086 · 2024: $1,429 · 2025: $2,328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,758 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,758.01 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,335.18 | 2020-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $863.45 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Celgene Corporation | $553.34 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $526.24 | 2021-2025 | Entyvio, Gattex |
| Ardelyx, INC. | $464.88 | 2022-2025 | Ibsrela |
| Boston Scientific Corporation | $285.11 | 2024 | Exalt Model D |
| Lilly USA, LLC | $254.35 | 2024-2025 | Omvoh, Zepbound |
| Qol Medical, LLC | $251.96 | 2022-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $248.79 | 2022-2025 | |
| Madrigal Pharmaceuticals | $193.26 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $135.84 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $117.94 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.06 | 2023-2025 | Xifaxan, Trulance |
| Pfizer INC. | $104.54 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.56 | 2023-2024 | Cyltezo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $65.00 | 2019 | |
| Teleflex LLC | $55.17 | 2022 | |
| Intercept Pharmaceuticals, INC. | $43.41 | 2023-2024 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $42.39 | 2023 | |
| Exact Sciences Corporation | $38.66 | 2025 | Cologuard Collection Kit |
| Braintree Laboratories, INC. | $29.14 | 2025 | Sutab, Suflave |
| Axonics, INC. | $26.83 | 2022 | |
| Ironwood Pharmaceuticals, INC | $22.25 | 2023 | Linzess |
| Capsovision, INC. | $15.09 | 2024 | Capsocam Plus |
| Novo Nordisk INC | $14.81 | 2025 | Wegovy |
| Evoke Pharma, INC. | $14.78 | 2025 | |
| Ferring Pharmaceuticals INC. | $14.21 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Corredine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.